



March 31, 2026

To Whom It May Concern

Company: Teijin Limited  
 Representative: Akimoto Uchikawa, President and CEO  
 Stock code: 3401 (Prime Market, Tokyo Stock Exchange)  
 Contact: Tetsuji Mikami, Deputy General Manager,  
 Corporate Communication Department  
 (Responsible for Investor Relations)  
 TEL: +81-3-3506-4395

### Notice regarding Revision of Full-Year Earnings Forecasts

Teijin Limited has revised the consolidated earnings forecasts for the fiscal year ending March 31, 2026 (April 1, 2025 to March 31, 2026), which were announced on February 4, 2026, in light of its recent performance.

#### Details

#### 1. Revision of consolidated earnings forecasts for the fiscal year ending March 31, 2026

	Revenue	Adjusted operating income	Operating income	Profit attributable to owners of parent	Basic earnings per share
Previously announced forecast (A)	million yen 860,000	million yen 25,000	million yen 5,000	million yen (10,000)	yen (51.85)
Revised forecast (B)	860,000	25,000	(75,000) - (85,000)	(85,000) - (95,000)	(440.76) - (492.62)
Change (B – A)	-	-	(80,000) - (90,000)	(75,000) - (85,000)	(388.91) - (440.77)
Change (%)	-	-	-	-	-
(Reference) Fiscal year ended March 2025	1,005,471	27,594	(71,828)	28,347	147.15

#### [Reasons for revision of earnings forecasts]

As announced in the Notice of Change in Equity Method Affiliates (Share Transfer) dated August 29, 2025, Teijin Limited resolved to transfer its shares in DuPont Teijin Advanced Papers (Japan) Limited and DuPont Teijin Advanced Papers (Asia) Limited. However, Completion of the share transfer is expected to be delayed into the fiscal year ending March 2027 (completion is scheduled for April 1, 2026).

In addition, the Company is considering selectively narrowing the portfolio of its pharmaceutical business, aside from the rare/intractable disease areas that it focuses on, to fundamentally improve

its profitability. As part of this measure, Teijin Pharma Limited, a consolidated subsidiary of the Company, reevaluated the recoverable amount of the sales rights for diabetes treatments, and concluded that there was a high likelihood of an impairment loss being recorded.

Furthermore, in light of the above, Teijin Limited and Teijin Pharma Limited reassessed the recoverability of deferred tax assets, concluding that the likelihood of needing to write down a part of the deferred tax assets has increased.

Due to the above factors, the Company has decided to make a downward revision to its previously announced forecasts for operating income, profit attributable to owners of parent, and basic earnings per share. Under the Company's policy of providing stable and sustainable dividends, its dividend forecast remains unchanged at 50 yen per share, including the interim dividend of 25 yen, for the fiscal year ending March 2026.

- End -